N/A
N=763
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
Ankylosing Spondylitis
Bottom Line
View on ClinicalTrials.gov: NCT04507763 ↗Enrolled (actual)
763
Serious AEs
—
Results posted
Oct 2021
Primary outcome: Primary: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Month 12 — 7.75; 7.74; 7.72; 7.78 Units on a scale — p=0.001
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Etanercept (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Oct 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Month 12 |
7.75; 7.74; 7.72; 7.78; -6.21; -5.44 | 0.001 sig |
| PRIMARY Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Month 12 |
8.32; 8.36; 8.46; 8.22; -6.86; -6.05 | 0.001 sig |
Summary
This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry
Eligibility Criteria
Inclusion Criteria
- Diagnosed AS patients.
- 18 years old
- Did not receive previous biological treatment for any reason
Exclusion Criteria
- Patients previously or currently treated with other biological therapies.
- Use of etanercept for less than 1 year duration.
Data sourced from ClinicalTrials.gov (NCT04507763). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.